Larvol Delta - Aviceda-Announces-Dosing-of-First-Patient-With-AVD104-a-Novel-GlycoMimetic-Nanoparticle-for-the-Treatment-of-Geographic-Atrophy-from-Macular-Degeneration-in-the-Phase-2-SIGLEC-Trial

AVD-104 - Aviceda

https://www.businesswire.com/news/home/20230601005051/en/Aviceda-Announces-Dosing-of-First-Patient-With-AVD-104-a-Novel-Glyco-Mimetic-Nanoparticle-for-the-Treatment-of-Geographic-Atrophy-from-Macular-Degeneration-in-the-Phase-2-SIGLEC-Trial

Jun 1, 2023

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next